Atlas Trials

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Clinical trial NCT06665178 · RECRUITING

Trial details

NCT number
NCT06665178
Sponsor
British Columbia Cancer Agency
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2025-03-31
Primary completion
2027-05-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.